Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)

John K. Petty, Ken He, Christopher Corless, John Vetto, Andrew D. Weinberg

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4+ ("helper") T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model. Methods: Sections of primary colon cancers, normal margins, mesenteric lymph nodes, and metastases were stained for OX-40 by immunohistochemistry. Cancer registry data were reviewed. Results: High levels of OX-40 positive tumor-infiltrating lymphocytes were found in 15 of 72 primary tumors. Thirty-one cases had prominent lymphocytic infiltrates expressing OX-40 at the invasive margin of the tumor. Overall, 50% of primary tumors showed high expression of OX-40. Nearly all mesenteric lymph nodes expressed OX-40, whether tumor was present or not. Normal margins of colon did not show high levels of OX-40. High OX-40 expression in the primary tumor correlated with better survival (mean survival high OX-40, 47 months, low OX-40, 35 months, P

Original languageEnglish (US)
Pages (from-to)512-518
Number of pages7
JournalAmerican Journal of Surgery
Volume183
Issue number5
DOIs
StatePublished - 2002

Fingerprint

Colorectal Neoplasms
T-Lymphocytes
Survival
Neoplasms
Colonic Neoplasms
Lymph Nodes
Tumor-Infiltrating Lymphocytes
Helper-Inducer T-Lymphocytes
Registries
Immunity
Colon
Animal Models
Immunohistochemistry
Neoplasm Metastasis

Keywords

  • Colorectal cancer
  • Human
  • Immunotherapy
  • OX-40 (CD134)
  • T cell

ASJC Scopus subject areas

  • Surgery

Cite this

Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). / Petty, John K.; He, Ken; Corless, Christopher; Vetto, John; Weinberg, Andrew D.

In: American Journal of Surgery, Vol. 183, No. 5, 2002, p. 512-518.

Research output: Contribution to journalArticle

@article{e8ac164071d9401e94c2f9256feb4215,
title = "Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)",
abstract = "Background: The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4+ ({"}helper{"}) T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model. Methods: Sections of primary colon cancers, normal margins, mesenteric lymph nodes, and metastases were stained for OX-40 by immunohistochemistry. Cancer registry data were reviewed. Results: High levels of OX-40 positive tumor-infiltrating lymphocytes were found in 15 of 72 primary tumors. Thirty-one cases had prominent lymphocytic infiltrates expressing OX-40 at the invasive margin of the tumor. Overall, 50{\%} of primary tumors showed high expression of OX-40. Nearly all mesenteric lymph nodes expressed OX-40, whether tumor was present or not. Normal margins of colon did not show high levels of OX-40. High OX-40 expression in the primary tumor correlated with better survival (mean survival high OX-40, 47 months, low OX-40, 35 months, P",
keywords = "Colorectal cancer, Human, Immunotherapy, OX-40 (CD134), T cell",
author = "Petty, {John K.} and Ken He and Christopher Corless and John Vetto and Weinberg, {Andrew D.}",
year = "2002",
doi = "10.1016/S0002-9610(02)00831-0",
language = "English (US)",
volume = "183",
pages = "512--518",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)

AU - Petty, John K.

AU - He, Ken

AU - Corless, Christopher

AU - Vetto, John

AU - Weinberg, Andrew D.

PY - 2002

Y1 - 2002

N2 - Background: The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4+ ("helper") T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model. Methods: Sections of primary colon cancers, normal margins, mesenteric lymph nodes, and metastases were stained for OX-40 by immunohistochemistry. Cancer registry data were reviewed. Results: High levels of OX-40 positive tumor-infiltrating lymphocytes were found in 15 of 72 primary tumors. Thirty-one cases had prominent lymphocytic infiltrates expressing OX-40 at the invasive margin of the tumor. Overall, 50% of primary tumors showed high expression of OX-40. Nearly all mesenteric lymph nodes expressed OX-40, whether tumor was present or not. Normal margins of colon did not show high levels of OX-40. High OX-40 expression in the primary tumor correlated with better survival (mean survival high OX-40, 47 months, low OX-40, 35 months, P

AB - Background: The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4+ ("helper") T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model. Methods: Sections of primary colon cancers, normal margins, mesenteric lymph nodes, and metastases were stained for OX-40 by immunohistochemistry. Cancer registry data were reviewed. Results: High levels of OX-40 positive tumor-infiltrating lymphocytes were found in 15 of 72 primary tumors. Thirty-one cases had prominent lymphocytic infiltrates expressing OX-40 at the invasive margin of the tumor. Overall, 50% of primary tumors showed high expression of OX-40. Nearly all mesenteric lymph nodes expressed OX-40, whether tumor was present or not. Normal margins of colon did not show high levels of OX-40. High OX-40 expression in the primary tumor correlated with better survival (mean survival high OX-40, 47 months, low OX-40, 35 months, P

KW - Colorectal cancer

KW - Human

KW - Immunotherapy

KW - OX-40 (CD134)

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=0036273628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036273628&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(02)00831-0

DO - 10.1016/S0002-9610(02)00831-0

M3 - Article

C2 - 12034383

AN - SCOPUS:0036273628

VL - 183

SP - 512

EP - 518

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5

ER -